Literature DB >> 1685599

Effects of endogenous dopamine on measures of [18F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons.

J Logan1, S L Dewey, A P Wolf, J S Fowler, J D Brodie, B Angrist, N D Volkow, S J Gatley.   

Abstract

The effect of endogenous dopamine on PET measures of radioligand binding is important to the measurement of receptor density (or availability) and neurotransmitter interactions in vivo. We recently reported that pretreatment with amphetamine, a drug which stimulates dopamine release, significantly reduced NMS binding in the baboon brain as determined by the product lambda k3 derived from the graphical analysis method for irreversible systems (lambda is the ratio of the forward to reverse plasma to tissue transport constants and k3 is proportional to receptor density) (Dewey et al.: Synapse 7:324-327, 1991). The purpose of this work is twofold: to evaluate the sensitivity and stability of the analysis method used for the NMS data and from simulation studies which include the competitive effects of dopamine on NMS binding to predict the effect of dopamine on the in vivo PET experiment. Using a measured plasma [18F]-NMS input function from a control study in a baboon, simulation data was numerically generated explicitly allowing competition between NMS and dopamine in the calculation. This data was analyzed using the same techniques as used for the experimental data and the results were compared to in vitro calculations. The following conclusions were reached: 1) The effect of dopamine on specific binding was found to be greater in vivo than in vitro because the in vitro equilibrium experiment is controlled only by the relative Kd's of tracer and dopamine while the in vivo experiment also depends upon the halftime of tracer in tissue which is controlled by the tissue-to-plasma transport constant; 2) Experimental evidence from rodent studies (Seeman et al.: Synapse 3:96-97, 1989) and the agreement between PET studies (Wong et al.: Science 234:1558-1563, 1986a) and postmortem human studies (Seeman et al.: Science 225:728-731, 1984) in schizophrenics suggest that NMS is not likely to be affected by normal levels of endogenous dopamine. From the calculations reported here the effective in vivo Kd of dopamine for the NMS binding site would have to be on the order of or greater than 100 nM, assuming a synaptic dopamine concentration of 20 nM, in order that this concentration of dopamine have little effect on NMS binding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685599     DOI: 10.1002/syn.890090306

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  17 in total

1.  First demonstration of in vivo mapping for regional brain monoacylglycerol lipase using PET with [11C]SAR127303.

Authors:  Tomoteru Yamasaki; Wakana Mori; Yiding Zhang; Akiko Hatori; Masayuki Fujinaga; Hidekatsu Wakizaka; Yusuke Kurihara; Lu Wang; Nobuki Nengaki; Tomoyuki Ohya; Steven H Liang; Ming-Rong Zhang
Journal:  Neuroimage       Date:  2018-05-05       Impact factor: 6.556

2.  Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain.

Authors:  H Tsukada; N Harada; S Nishiyama; H Ohba; T Kakiuchi
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

3.  Mapping human brain fatty acid amide hydrolase activity with PET.

Authors:  Pablo M Rusjan; Alan A Wilson; Romina Mizrahi; Isabelle Boileau; Sofia E Chavez; Nancy J Lobaugh; Stephen J Kish; Sylvain Houle; Junchao Tong
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-05       Impact factor: 6.200

4.  Low monoamine oxidase B in peripheral organs in smokers.

Authors:  Joanna S Fowler; Jean Logan; Gene-Jack Wang; Nora D Volkow; Frank Telang; Wei Zhu; Dinko Franceschi; Naomi Pappas; Richard Ferrieri; Colleen Shea; Victor Garza; Youwen Xu; David Schlyer; S John Gatley; Yu-Shin Ding; David Alexoff; Donald Warner; Noelwah Netusil; Pauline Carter; Millard Jayne; Payton King; Paul Vaska
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

5.  Dopamine and depression--striatal dopamine D2 receptor SPECT before and after antidepressant therapy.

Authors:  D Ebert; H Feistel; T Loew; A Pirner
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

6.  Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.

Authors:  Joanna S Fowler; Jean Logan; Albert J Azzaro; Robert M Fielding; Wei Zhu; Amy K Poshusta; Daniel Burch; Barry Brand; James Free; Mahnaz Asgharnejad; Gene-Jack Wang; Frank Telang; Barbara Hubbard; Millard Jayne; Payton King; Pauline Carter; Scott Carter; Youwen Xu; Colleen Shea; Lisa Muench; David Alexoff; Elena Shumay; Michael Schueller; Donald Warner; Karen Apelskog-Torres
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

Review 7.  The dopaminergic basis of human behaviors: A review of molecular imaging studies.

Authors:  Alice Egerton; Mitul A Mehta; Andrew J Montgomery; Julia M Lappin; Oliver D Howes; Suzanne J Reeves; Vincent J Cunningham; Paul M Grasby
Journal:  Neurosci Biobehav Rev       Date:  2009-05-27       Impact factor: 8.989

8.  Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.

Authors:  S L Dewey; G S Smith; J Logan; J D Brodie; P Simkowitz; R R MacGregor; J S Fowler; N D Volkow; A P Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

9.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

Authors:  M Laruelle; A Abi-Dargham; C H van Dyck; R Gil; C D D'Souza; J Erdos; E McCance; W Rosenblatt; C Fingado; S S Zoghbi; R M Baldwin; J P Seibyl; J H Krystal; D S Charney; R B Innis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

10.  A receptor-based model for dopamine-induced fMRI signal.

Authors:  Joseph B Mandeville; Christin Y M Sander; Bruce G Jenkins; Jacob M Hooker; Ciprian Catana; Wim Vanduffel; Nathaniel M Alpert; Bruce R Rosen; Marc D Normandin
Journal:  Neuroimage       Date:  2013-03-01       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.